Stimulon QS-21adjuvant data

CBCX's adjuvant was the most effective of several tested in producing a consistent antibody response to a vaccine being tested in three groups of six patients each with stage III melanoma. The Phase I, randomized, double-blind study was reported in Specific Immunotherapy of Cancer with Vaccines.

All six of the patients given QS-21 showed an IgG response, whereas only one of the 12 in the other two groups had an increase in IgG titer. The ganglioside-based vaccine has had weak or no immunogenic effects without adjuvants. ...